This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
The programme will take place on the 2nd Sunday of every month
Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies
Encourages working women to practice self-care
Overall investment in the US facility is estimated around US$50 million
There are 38.4 million people with diabetes in the United States
Subscribe To Our Newsletter & Stay Updated